22nd Century Group, Inc. (XXII) News
Filter XXII News Items
XXII News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XXII News Highlights
- For XXII, its 30 day story count is now at 3.
- Over the past 24 days, the trend for XXII's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- VLN, CDMO and HOUR are the most mentioned tickers in articles about XXII.
Latest XXII News From Around the Web
Below are the latest news stories about 22ND CENTURY GROUP INC that investors may wish to consider to help them evaluate XXII as an investment opportunity.
22nd Century Group (XXII) Announces Participation in the LD Micro Invitational XIIIBUFFALO, N.Y., June 02, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private o |
22nd Century Group (XXII) Highlights Recent TCORS Symposium FindingsFDA Authorized VLN® Products from 22nd Century Group Provide Key Support to Menthol Ban and Reduced Nicotine Content Policies Currently Advancing in the U.S. Decades of Clinical Research Affirm the Strength of Proposed FDA Policies in Reducing the Harms of Smoking Opposes Efforts by Tobacco Interests to Interfere with Advancement of FDA Policies to Reduce Adult Smoking BUFFALO, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicat |
22nd Century Group (Nasdaq: XXII) Reports First Quarter 2023 Financial Results, Introduces 2023 Full Year Revenue OutlookReadying Q2 VLN® Commercial Sales in California, Texas and Florida, Booking Additional Launches Targeting 18 States Throughout 2023Advancing VLN® Pilot Programs in Switzerland, Japan, and South KoreaDelivered Record GVB Ingredient Volumes as Dominant Supplier in North AmericaSigns Exclusive CDMO Plus Distribution Agreements Worth More Than $140 Million with Cookies and Old PalFirst Quarter 2023 Net Revenues $22.0 Million, Up 143% from the First Quarter 2022Provides Initial 2023 Revenue Outlook o |
22nd Century Group (Nasdaq: XXII) to Announce First Quarter 2023 Results on May 9, 2023BUFFALO, N.Y., May 03, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Tuesday, May 9, 2023, at 10:00 AM ET to discuss its 2023 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, James A. Mish, chief executive officer; John Miller, president of |
22nd Century Group (XXII) Announces Strategic License, Manufacturing and Distribution Agreement with Old PalSecond Leading Consumer Hemp/Cannabis Brand Adopts 22nd Century’s Turn-Key Contract Development and Manufacturing Plus Distribution (CDMO+D) Solution Previously Announced Cookies Agreement Now Targeting More Than 200 Wholesale Distributors Combined Cumulative Value of New License and Distribution Agreements Executed to Date Expected to Exceed $140 Million Over Contract Terms BUFFALO, N.Y., May 02, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company d |
22nd Century Group Launches New Private Label Brand with Top U.S. C-Store ChainPinnacle Cigarette Brand to Be Sold in up to 1,700 U.S. Retail Locations in up to 27 StatesDramatically Increases CDMO Revenue and Business Unit Profitability Toward Cash Positive, in Line with Recent Expectations Buffalo, New York--(Newsfile Corp. - April 18, 2023) - 22nd Century Group, Inc. (NASDAQ: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that it has commenced ... |
22nd Century Group (XXII) Announces Fully Integrated, Single-Source Strategic License, Manufacturing and Distribution Agreement with CookiesLaunches Turn-Key Contract Development and Manufacturing Plus Distribution (CDMO+D) Solution for Industry Leading Hemp/Cannabis Brands Highly Accretive Transformative Deal Utilizes Entire 22nd Century Value Chain, from Receptor Science to Category Management in Retail Distribution with Most Recognized Cannabis Brand in the World BUFFALO, N.Y., April 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nic |
22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateAccelerates VLN® Launch with Key National Distribution AgreementsLaunching VLN® in Texas, California and Florida with New National Scale Distributor and Retail PartnersScaling Hemp/Cannabis Revenue and Gross Margin to Achieve Cash-Positive Operating Results in First Half 2024; Executing New Fully Verticalized Major Retail Category Management Services AgreementsFourth Quarter 2022 Net Revenues $19.2 Million, Up 141% from the Fourth Quarter 2021New $21.1 Million Senior Secured Credit Facility Expa |
22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth InitiativesSupports Accelerated Expansion of VLN Multi-State Retail Channels, GVB Global Ingredients and CDMO BusinessBUFFALO, N.Y., March 03, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the world’s leading biotechnology company dedicated to improving health with reduced nicotine tobacco and advanced plant technologies in both hemp/cannabis and hops, today announced a new $21 million senior secured debenture financing to support increased working capital needs related to the significa |
22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor ConferenceBUFFALO, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that the Company will be participating in one-on-one meetings during the 35th Annual Roth Conference, to be held March 12-14, 2023 in Orange County, California. Investors and attendees that would like to schedule a meeting with 22nd Century’s manag |